Previous close | 37.75 |
Open | 37.68 |
Bid | 37.17 x 100 |
Ask | 37.28 x 100 |
Day's range | 37.10 - 37.90 |
52-week range | 22.11 - 53.18 |
Volume | |
Avg. volume | 909,698 |
Market cap | 2.453B |
Beta (5Y monthly) | 1.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celldex Therapeutics ( NASDAQ:CLDX ) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened...
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.